HALO vs. NVO: Halozyme Therapeutics vs. Novo Nordisk Stock Comparison

Company Profile

Halozyme Therapeutics (HALO) and Novo Nordisk (NVO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while NVO is classified in Pharmaceuticals.

Halozyme Therapeutics (HALO) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Halozyme Therapeutics (HALO) at 216.38% is the standout with ROE above its industry range; Novo Nordisk (NVO) at 58.38% also sits in the top quartile.

Both Halozyme Therapeutics (HALO) at 26.93% and Novo Nordisk (NVO) at 33.92% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Halozyme Therapeutics (HALO) at 59.84% and Novo Nordisk (NVO) at 40.05% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Halozyme Therapeutics (HALO) at 37.55% and Novo Nordisk (NVO) at 6.43% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Halozyme Therapeutics (HALO) at -25.36% and Novo Nordisk (NVO) at 1.77% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Novo Nordisk (NVO) at 0.85 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVO.

Only one side’s leverage can be read here: Novo Nordisk (NVO) carries debt-to-equity ratio of 0.62 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

Financial Strength Metrics

Dividends

Halozyme Therapeutics (HALO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a yield of 29.03%, ranking against industry peers normally.

Halozyme Therapeutics (HALO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a payout of 45.36%, ranking against industry peers normally.

Dividend Metrics

Valuation

Novo Nordisk (NVO) at 10.18 sits in the cheaper P/E ratio quartile, while Halozyme Therapeutics (HALO) at 25.91 is closer to its industry’s usual earnings multiple — a discount for NVO, though growth and earnings durability still matter.

Novo Nordisk (NVO) at 0.53 sits in the cheaper P/S ratio quartile while Halozyme Therapeutics (HALO) at 6.55 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Novo Nordisk (NVO) reports 5.43, ranking against industry peers normally.

Valuation Metrics